Bifogade filer
Neola Medical granted U.S. patent for disposable probes, strengthening future revenue model in target market
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Neola Medical AB (publ) announces today that the company has been granted a U.S. patent protecting its disposable probes for the medical device Neola®. The advanced light and detector probes are used for continuous lung monitoring of preterm born babies. To monitor both lungs, two probe sets are required and are changed daily, making these disposables central to Neola Medical’s scalable revenue model. The U.S. patent secure proprietary protection in the company’s key target market and complement the already granted European patent. A corresponding application is pending in China.
“These disposables are central to our future business model, where recurring revenues from daily probe replacements are expected to provide significant leverage. Securing patent protection in the U.S. strengthens our competitive position in our most important target market and protects our unique optical design,” says CEO Hanna Sjöström.
About the patent
The granted patent belongs to the patent family “A light diffuser and a method for assembling the same” and protects Neola Medical’s innovation for achieving uniform, diffuse light distribution from the dermal emitter probe. This design is essential for enabling safe, non-invasive, and continuous lung monitoring through optical spectroscopy.